Dilution of Per-Share Value Through Third-Party Allotments and Other Transactions
First written in FY2016. 35 of 42 entries say "Materialised", first in FY2017-Q1. Latest entry: 2026-11-13.
Fruta Fruta moved to the "Worse" side of this theme in 2016, 5 years before the typical company in this theme (2021).
The whole theme swung hardest in 2017: 19 of 37 companies on the "Worse" side.
12 other companies' latest entry also says "Mitigated".
- FY2027-H1MaterialisedAnnual report
「Number of such bonds with stock acquisition rights exercised during the interim accounting period (units) 97,350」Number of shares delivered in connection with exercises during the interim accounting period (shares) 9,735,000」
The exercise of the 14th series of stock acquisition rights resulted in the issuance of 9,735,000 shares during the interim accounting period, and dilution progressed in actual terms. As of the interim period-end, 28,425,000 shares remained scheduled for issuance upon exercise of the unexercised rights. - FY2026MaterialisedAnnual report
「30 August 2025–31 March 2026 Common shares 23,955,000」
During the fiscal year, 26,755,000 common shares were added through the exercise of stock acquisition rights and other transactions, and dilution progressed through actual share issuance. As of the fiscal year-end, 28,425,000 shares remained scheduled for issuance upon exercise of the unexercised rights. - FY2026-H1MaterialisedAnnual report
「Number of such bonds with stock acquisition rights exercised during the interim accounting period (units) 74,400」Number of shares delivered in connection with exercises during the interim accounting period (shares) 7,440,000」
The exercise of the 12th series of stock acquisition rights resulted in the issuance of 7,440,000 shares, and dilution progressed through actual share issuance. Meanwhile, as of the end of the interim accounting period, an unexercised balance equivalent to a total of 47,740,000 shares remained for the 12th through 14th series. - FY2025MaterialisedAnnual report
「1 April 2024–31 March 2025 Class A shares Common shares 32,700,000 79,639,569」
During the fiscal year, 32,700,000 common shares were added through the exercise of stock acquisition rights and other transactions. Meanwhile, 55,180,000 potential shares from unexercised stock acquisition rights remained, and dilution continued. - FY2025-H1MaterialisedAnnual report
「This resulted from proceeds of ¥1,101.237 million from the issuance of shares upon the exercise of stock acquisition rights.」
During the interim accounting period, 17,370,000 common shares were added through the exercise of stock acquisition rights, and both capital and the capital reserve increased by ¥551.468 million. Dilution continued to progress through actual share issuance. - FY2024MaterialisedAnnual report
「At a meeting of the Board of Directors held on 13 November 2023, the Company resolved to issue the 11th through 13th series and the 14th and 15th series of stock acquisition rights, with an exercise deadline of 17 December 2030. As of the end of March 2024, a total of 878,800 stock acquisition rights remained unexercised, and a total of 87,880,000 shares were to be issued through their exercise by that time.」
While the partial exercise of the 11th series of stock acquisition rights resulted in the issuance of 4,240,000 shares, an unexercised balance equivalent to 87,880,000 shares remained for the 11th through 15th series, and the dilution exposure continued. - FY2024-Q3MaterialisedAnnual report
「As of the end of December 2023, 918,600 stock acquisition rights remained unexercised, and 91,860,000 common shares were to be issued through their exercise by the deadline. In addition, following the grant at an extraordinary general meeting of shareholders held on 14 September 2021 of an acquisition request right for Class A shares with common shares as consideration, 26,244,140 common shares were to be issued if the right was exercised in the future, and 18,242,360 common shares had been issued as of the end of December 2023.」
While the unexercised balance equivalent to 91,860,000 shares remained for the 11th through 15th series of stock acquisition rights, issuance of common shares through the acquisition request right attached to the Class A shares progressed to 18,242,360 shares, and dilution continued to materialize. - FY2024-Q2WorsenedAnnual report
「11th series of stock acquisition rights: 182,400 units 12th series of stock acquisition rights: 182,400 units 13th series of stock acquisition rights: 182,400 units. Potential shares from these issuances: 54,720,000 shares.」Total number of stock acquisition rights exercisable from time to time: 374,000 units; potential shares from this issuance: 37,400,000 shares.」
Plans to issue stock acquisition rights after the filing indicated a total of 92,120,000 potential shares, substantially expanding the dilution exposure. The issuances were subject to shareholder approval and other conditions and had not been completed as of the end of the quarter. - FY2024-Q1MaterialisedAnnual report
「1 April 2023–30 June 2023 (Note) Common shares 772,000 Class A shares △200」
The exercise of the provision allowing Class A shares to be acquired in exchange for common shares resulted in the issuance of 772,000 common shares during the first quarter. A further 2,123,000 common shares had been issued by the filing date, and dilution progressed. - FY2023-Q2MaterialisedAnnual report
「Following the grant at an extraordinary general meeting of shareholders held on 14 September 2021 of an acquisition request right for Class A shares with common shares as consideration, 26,244,140 common shares were to be issued if the right was exercised in the future, and 14,146,900 common shares had been issued as of the end of September 2022.」
The exercise of the acquisition request right attached to the Class A shares resulted in common share issuance reaching 14,146,900 shares, and dilution materialized further from the previous quarter. The unexercised balance of 1,712,384 tenth-series stock acquisition rights also remained outstanding. - FY2023-Q1MaterialisedAnnual report
「As of the end of June 2022, 1,712,384 stock acquisition rights remained unexercised, and 1,712,384 shares were to be issued through their exercise by that time. As of the end of June 2022, 12,267,080 common shares had been issued.」
While unexercised tenth-series stock acquisition rights remained outstanding, issuance of common shares through the exercise of the acquisition request right attached to the Class A shares progressed to 12,267,080 shares, and dilution continued. - FY2022MaterialisedAnnual report
「At a meeting of the Board of Directors held on 13 August 2020, the Company resolved to issue the tenth series of stock acquisition rights, with an exercise deadline of 6 October 2023. As of the end of March 2022, 1,712,384 stock acquisition rights remained unexercised, and 1,712,384 shares were to be issued through their exercise by that time. In addition, following the grant at an extraordinary general meeting of shareholders held on 14 September 2021 of an acquisition request right for Class A shares with common shares as consideration, 26,244,140 common shares were to be issued if the right was exercised in the future, and 9,951,080 common shares had been issued as of the end of March 2022.」
During the fiscal year, 4,088,800 tenth-series stock acquisition rights were exercised, while 1,712,384 remained unexercised. Issuance of common shares through the acquisition request right attached to the Class A shares progressed to 9,951,080 shares, and dilution continued. - FY2022-Q3MaterialisedAnnual report
「As of the end of December 2021, 1,712,384 stock acquisition rights remained unexercised, and 1,712,384 shares were to be issued through their exercise by the deadline. In addition, following the grant at an extraordinary general meeting of shareholders held on 14 September 2021 of an acquisition request right for Class A shares with common shares as consideration, 26,244,140 common shares were to be issued if the right was exercised in the future, and 7,866,680 common shares had been issued as of the end of December 2021.」
Cumulative exercises of the tenth series of stock acquisition rights reached 8,730,600, and 7,866,680 common shares were actually issued through the acquisition request right attached to the Class A shares. Potential dilution remains. - FY2022-Q2WorsenedAnnual report
「As of the end of September 2021, 1,947,984 stock acquisition rights remained unexercised, and 1,947,984 shares were to be issued through their exercise by the deadline. In addition, following the grant at an extraordinary general meeting of shareholders held on 14 September 2021 of an acquisition request right for Class A shares with common shares as consideration, 26,244,140 common shares were to be issued if the acquisition request right was exercised in the future.」
In addition to the unexercised tenth-series stock acquisition rights, the acquisition request right attached to the Class A shares created the possibility of issuing up to 26,244,140 common shares, substantially expanding the dilution exposure. - FY2022-Q1MaterialisedAnnual report
「During the first quarter, stock acquisition rights attached to bonds with stock acquisition rights subject to exercise price adjustment provisions were exercised as follows.」Number of such bonds with stock acquisition rights exercised during the quarter (units) 2,316,000」As of the end of June 2021, 3,485,184 stock acquisition rights remained unexercised.」
During the quarter, 2,316,000 tenth-series stock acquisition rights were exercised, bringing cumulative exercises to 6,957,800. Meanwhile, 3,485,184 remained unexercised, and the dilution risk continued to progress through actual share issuance. - FY2021MaterialisedAnnual report
「At a meeting of the Board of Directors held on 13 August 2020, the Company resolved to issue the tenth series of stock acquisition rights, with an exercise deadline of 6 October 2023. As of the end of March 2021, 5,801,184 stock acquisition rights remained unexercised, and 5,801,184 shares were to be issued through their exercise by that time.」
The exercise of the tenth series of stock acquisition rights resulted in the issuance of 4,641,800 shares during the fiscal year, leaving an unexercised balance equivalent to 5,801,184 shares. Dilution continued to progress through actual share issuance. - FY2021-Q3MaterialisedAnnual report
「At an extraordinary meeting of the Board of Directors held on 13 August 2020, the Company resolved to issue the tenth series of stock acquisition rights. The number of shares underlying the rights was 10,442,984, and the exercise deadline was 6 October 2023. As of the end of December 2020, 8,117,184 stock acquisition rights remained unexercised, and 8,117,184 shares were to be issued through their exercise by the deadline.」
During the third quarter, 2,225,800 shares represented by the tenth series of stock acquisition rights were issued upon exercise, reducing the unexercised balance from the equivalent of 10,342,984 shares to 8,117,184. Dilution continued to progress through actual share issuance. - FY2021-Q2MaterialisedAnnual report
「At an extraordinary meeting of the Board of Directors held on 13 August 2020, the Company resolved to issue the tenth series of stock acquisition rights. The number of shares underlying the rights was 10,442,984, and the exercise deadline was 6 October 2023. As of the end of September 2020, 10,342,984 stock acquisition rights remained unexercised, and 10,342,984 shares were to be issued through their exercise by the deadline.」
The tenth series of stock acquisition rights was issued, and 100,000 were exercised during the second quarter. Of the 10,342,984 shares represented by the unexercised balance, the dilution risk has materialized and continues as an actual capital transaction. - FY2021-Q1WorsenedAnnual report
「As of 30 June 2020, all 3,175,200 shares underlying those stock acquisition rights had been issued because all 31,752 seventh-series stock acquisition rights were exercised during the cumulative first-quarter period.」Potential shares from this issuance 10,442,984 shares (1 share per stock acquisition right)」In principle, approximately 3 years」
All of the seventh-series stock acquisition rights were exercised, eliminating the previous dilution risk. Meanwhile, a plan to issue 10,442,984 tenth-series stock acquisition rights was disclosed as a subsequent event, creating new dilution exposure from potential shares. - FY2020MaterialisedAnnual report
「The increase in issued common shares resulted from the exercise of stock acquisition rights for 2,600,000 shares.」As of the end of March 2020, 31,752 stock acquisition rights remained unexercised, and 3,175,200 shares were to be issued through their exercise by that time.」
While the exercise of the seventh series of stock acquisition rights resulted in the issuance of 2,600,000 common shares, potential shares of 3,175,200 remained, and the dilution risk persisted. - FY2020-Q3WorsenedAnnual report
「Potential shares from this issuance 5,775,200 shares」
The seventh series of stock acquisition rights issued to EVO FUND created 5,775,200 potential shares, substantially expanding the dilution exposure. In addition, 15,000 rights had been exercised by the end of January 2020, and actual share issuance was also progressing. - FY2019-Q2MaterialisedAnnual report
「12 September 2018 (Note 2) 20,000 1,949,629 6,612 709,917 6,612 673,641」
An additional 20,000 shares were issued through the exercise of stock acquisition rights on 12 September, and dilution continued to progress as an actual capital transaction. - FY2019-Q1MaterialisedAnnual report
「Between 1 July and 31 July 2018, the total number of issued shares increased by 7,610, capital increased by ¥2.5 million and the capital reserve increased by ¥2.5 million through the exercise of stock acquisition rights attached to convertible bonds with stock acquisition rights.」
A further 7,610 shares were issued through the exercise of stock acquisition rights attached to convertible bonds with stock acquisition rights after the quarter-end, and dilution continued to materialize. - FY2018MaterialisedAnnual report
「The number of issued common shares increased by 671,853 through the issuance of 304,400 shares in a third-party allotment, the conversion of 265,953 shares under convertible bonds with stock acquisition rights and the exercise of stock acquisition rights for 101,500 shares.」
The number of issued shares increased by 671,853 during the full fiscal year through the third-party allotment, conversion of the convertible bonds and exercise of the stock acquisition rights. Potential dilution of 905,000 shares and other amounts under the sixth series of stock acquisition rights also remains. - FY2018-Q3MaterialisedAnnual report
「On 29 November 2017, we conducted a third-party allotment and issued convertible bonds with stock acquisition rights and stock acquisition rights to Asrapport Dining and Milestone Capital Management Co., Ltd.」
The issuance of the 304,400 new shares, 152,207 shares represented by the convertible bonds with stock acquisition rights and 905,000 shares represented by the stock acquisition rights disclosed in the previous quarter was completed, and the dilution exposure materialized as a capital transaction. - FY2018-Q2WorsenedAnnual report
「At a meeting of the Board of Directors held on 13 November 2017, the Company resolved to issue new shares, the second series of convertible bonds with stock acquisition rights and the sixth series of stock acquisition rights, with Asrapport Dining Co., Ltd. (hereinafter, “Asrapport Dining”) and Milestone Capital Management Co., Ltd. (hereinafter, “Milestone”) as the allottees.」
In addition to the 304,400 new shares scheduled for payment on 29 November, the company disclosed 152,207 potential shares from the convertible bonds and 905,000 potential shares from the stock acquisition rights, expanding its future dilution exposure. - FY2018-Q1MaterialisedAnnual report
「1 April 2017–30 June 2017 (Note 1) 30,339 1,280,505 12,500 474,015 12,500 437,738」This represents an increase resulting from the exercise of stock acquisition rights.」
During the first quarter, 30,339 shares were added through the exercise of stock acquisition rights, bringing total issued shares to 1,280,505. As of the filing date, the total had increased further to 1,292,640, and dilution had progressed further. - FY2017MaterialisedAnnual report
「The number of issued shares increased by 240,266 through the issuance of 175,000 shares in a third-party allotment, the conversion of 59,466 shares under convertible bonds with stock acquisition rights and the exercise of stock acquisition rights for 5,800 shares.」
The number of issued shares actually increased by 240,266 through the third-party allotment, conversion of the convertible bonds and exercise of the stock acquisition rights, and the dilution risk materialized through capital transactions for the full fiscal year. - FY2017-Q3MaterialisedAnnual report
「1 October 2016–31 December 2016 (Note) 4,100 1,250,166 1,025 461,515」
A further 4,100 shares were issued through the exercise of stock acquisition rights during the third quarter, and dilution continued to materialize as an actual capital transaction. - FY2017-Q2MaterialisedAnnual report
「13 July 2016 (Note 2) 59,466 1,244,366 24,500 460,065」1 July 2016–30 September 2016 (Note 3) 1,700 1,246,066 425 460,490」
An additional 59,466 shares were issued through the conversion of convertible bonds with stock acquisition rights and 1,700 shares through the exercise of stock acquisition rights, further reflecting dilution as an actual capital transaction. - FY2017-Q1MaterialisedAnnual report
「Payment was completed on 8 July 2016.」
The planned issuance and payment for the new shares through a third-party allotment, convertible bonds with stock acquisition rights and stock acquisition rights were completed, and the dilution risk materialized as an actual capital transaction. - FY2016First statedAnnual report
「The issuance of these new shares, these convertible bonds with stock acquisition rights and these stock acquisition rights may dilute the per-share value and ownership percentages of the Company's common shares, adversely affecting the Company's share price.」
The planned issuance comprises 175,000 shares through a third-party allotment, 247,572 shares upon conversion and 185,000 shares upon exercise of stock acquisition rights.